Welcome to the first edition of Digital Trials Digest — ObvioHealth's quarterly look at what's new in ObvioGo, where the industry is heading, and the partnerships shaping the future of decentralized trials.

Big news: built-in eSignature

ObvioGo introduced a fully in-house, compliant eSignature capability, replacing reliance on third-party tools — giving study teams greater workflow flexibility, improved cost efficiency, and enhanced scalability for trials of any size.

Platform spotlight

• Template Library. Teams can now create and reuse standardized activity templates across multiple trials, with built-in permissions and search tools for consistency and control at scale.
• Out-of-Window Data Submissions. Study Manager now allows teams to reinstate eligible expired, skipped, or terminated activities and enter missing data on a participant's behalf, recovering data that would otherwise go uncollected.

Company news & partnerships

ObvioHealth announced an integrated solutions collaboration with SPRIM PRO, and a three-year agreement making ObvioGo the preferred digital trial platform for Vaxxas' needle-free HD-MAP vaccine studies.

Thought leadership: caregiver-centric eDiary design

In a webinar with SPRIM PRO, ObvioHealth's Director of Product Enablement, Cristina Ransom Mojica, shared best practices in caregiver-centric eDiary design that strengthen compliance and data quality in infant formula trials.

Client spotlight: MiHelper

MiHelper's decentralized migraine study showed how ObvioGo drives faster enrollment, stronger engagement, and cleaner data in CNS research — moving 1,400+ participants through automated consent screening, achieving 81% retention, processing 75,889 activities, and reaching database lock with zero critical items.

Coming soon in ObvioGo

An Ad Hoc Activity Review screen, an eSignature countersignature workflow for investigators and study staff, and native Assent support for minors and dependent participants.

Download the full Q1 2026 issue (PDF) → for details, upcoming events, and more.